Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.GRI · Entity 8336 | Chief Medical Officer | April 21, 2023 | April 25, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date April 21, 2023 · Filed April 25, 2023
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2023 Filed Apr 24, 2023 18:29 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantCommon Stock | 172,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001824293-23-000103 · wf-form4_168237538206040.xml · nonDerivative · entry 1 Agro Albert · CIK 0001661357 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,189 F1 · shares: Received in exchange for 4,600,000 shares of common stock of GRI Bio, Inc. ("GRI"), pursuant to the Agreement and Plan of Merger, dated December 13, 2022, by and among Vallon Pharmaceuticals, Inc. (the "Company"), Vallon Merger Sub, Inc. and GRI Bio, Inc. (the "Merger"). Per the terms of the Merger, each share of GRI common stock was converted into the right to receive 0.0374 shares of the Company's common stock. In connection with the Merger, the Company effected a reverse stock split of the Company's common stock at a ratio of 1-for-30 (the "Reverse Split"). Unless noted otherwise, all references to share amounts in this Form 4 reflect the Reverse Split. F1 · price: Received in exchange for 4,600,000 shares of common stock of GRI Bio, Inc. ("GRI"), pursuant to the Agreement and Plan of Merger, dated December 13, 2022, by and among Vallon Pharmaceuticals, Inc. (the "Company"), Vallon Merger Sub, Inc. and GRI Bio, Inc. (the "Merger"). Per the terms of the Merger, each share of GRI common stock was converted into the right to receive 0.0374 shares of the Company's common stock. In connection with the Merger, the Company effected a reverse stock split of the Company's common stock at a ratio of 1-for-30 (the "Reverse Split"). Unless noted otherwise, all references to share amounts in this Form 4 reflect the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.